Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review
PDF | HTML | How to cite
Metrics: PDF 1420 views | HTML 2313 views | ?
Zhe Zhang1, Yishan Chen1, Mingxia Ma1, Junli Hao1, Rui Ding1, Lixin Han1, Jiayun Zou1, Lina Zhang1, Qin Meng2, Xiujuan Qu1, Yunpeng Liu1 and Mingfang Zhao1
1 Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China
2 Suzhou Junmeng Bioscience Co., Ltd, Suzhou City, Jiangsu Province, China
Mingfang Zhao, email:
Yunpeng Liu, email:
Keywords: pulmonary carcinosarcoma, programmed cell death protein-1 (PD-1), nivolumab, immunotherapy
Received: February 04, 2017 Accepted: May 22, 2017 Published: July 07, 2017
Immunotherapy has recently become a new focus for the treatment of malignant tumors following the surgery, chemotherapy, radiotherapy, and molecular targeted therapy. Nivolumab, a human monoclonal antibody, is the first programmed cell death protein-1 (PD-1) inhibitor, which can prohibit the interaction of its ligand (PD-L1), restoring the immune response of T cells, and enhancing the recognition of tumor cells by the immune system. Pulmonary carcinosarcoma is an uncommon but highly aggressive tumor type with a poor prognosis. We described a case of pulmonary carcinosarcoma, with the positive expression of PD-L1, obtained a significant benefit from Nivolumab treatment in a 64-year-old Chinese man, which give us a clue that patients with pulmonary carcinosarcoma may benefit fromanti-PD-1 immunotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.